<DOC>
	<DOCNO>NCT00285259</DOCNO>
	<brief_summary>The purpose trial evaluate CMV vaccine give related donor/recipient pair ( donor prior peripheral blood stem cell donation CMV-seropositive recipient transplantation ) CMV-seropositive recipient-only subject ( relate unrelated ) determine incidence rate CMV infection , disease , complication immunosuppression and/or transplantation . The outcomes group receive CMV vaccine compare outcome group receive placebo vaccine see clinical benefit . For trial , donor recipient must match HLA genotype ( match 5/6 6/6 HLA locus ) .</brief_summary>
	<brief_title>Cytomegalovirus ( CMV ) Vaccine Donors Recipients Undergoing Allogeneic Hematopoietic Cell Transplant ( HCT )</brief_title>
	<detailed_description>This study run Vical record transfer Astellas 1/8/2013 . Trial enroll 240 subject ( 160 recipient 80 donor ) . Qualified donor and/or CMV-seropositive recipient ( donor/recipient pair recipient-only subject ) assign randomly receive either CMV vaccine placebo vaccine . Donors receive 3 vaccine prior donation recipient receive 1 vaccine pretransplant three vaccine posttransplant . Recipients follow 1 year transplant evaluate safety vaccine see clinical benefit group receive CMV vaccine . The incidence rate CMV infection , disease , complication immunosuppression and/or transplantation study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>male female age 1865 5/6 6/6 classic HLA allelematched donor plan GCSFmobilized peripheral blood stem cell transplant CMVseropositive recipient plan transplant minimal Tcell depletion Acute Lymphoblastic Leukemia ( ALL ) first second remission ; Acute Myeloid Leukemia ( AML ) first second remission ; Chronic Myelogenous Leukemia ( CML ) first chronic accelerated phase , second chronic phase ; Hodgkin 's nonHodgkin 's lymphoma ; myelodysplastic syndrome plan prophylactic cytomegalovirus antiviral therapy plan immunosuppression alemtuzumab ( CAMPATHIH ) plan prophylactic therapy CMV immunoglobulin autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>infectious disease</keyword>
	<keyword>viremia</keyword>
	<keyword>cytomegalovirus disease</keyword>
	<keyword>stem cell transplant</keyword>
	<keyword>allogeneic</keyword>
	<keyword>bone marrow transplant</keyword>
	<keyword>hematopoietic cell transplant</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>